摘要
目的:系统评价复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞的有效性。方法:计算机检索PubMed、Embase、Web of Science、CNKI、万方和维普数据库等,搜集关于复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞的随机对照试验(RCT),检索时限均从建库至2023年5月25日。采用RoB2.0对纳入研究进行偏倚风险评估,采用RevMan5.4软件进行Meta分析。结果:共纳入8研究,包括702名患者。结果显示,与对照组相比,联合治疗组可以提高患者综合疗效有效率[OR=1.23,CI(1.16,1.32),P<0.00001],在血液流变学指标方面,全血粘度[MD=-0.76,95%CI(-1.32,-0.20),P=0.008]、血浆粘度[MD=-0.37,95%CI(-0.47,-0.27),P<0.00001]、红细胞聚集指数[MD=-0.96,95%CI(-1.09,-0.84),P<0.00001]、红细胞比容[MD=-0.09,95%CI(-0.11,-0.07),P<0.00001]、纤维蛋白原[MD=-0.62,95%CI(-0.90,-0.33),P<0.00001]。结论:Meta分析结果表明,复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞可能改善血液流变学指标,能明显提升综合疗效有效率。但由于原始文献质量较低,分析结果具有一定限制性,故上述结论尚待更多高质量研究予以验证。
Objective:To systematically evaluate the effectiveness of Fufang Xueshuantong combined with Fufang anisodine injection in the treatment of retinal vein obstruction.Method:Retrieved from PubMed,Embase,Web of Science,CNKI,VIP,and Wanfang,randomized controlled trials(RCTs)about Xueshuantong combined with compound anisodine injection in the treatment of retinal vein obstruction were collected during the inception to May 25,2023.After literature screening and data extraction,the qualities of included literature were evaluated and rated by using RoB 2.0.Meta-analysis were performed with RevMan 5.3 software.Result:8 studies were included,with a total sample of 702 patients.Compared with the control group,Meta-analysis results showed that the combined group had better effect reflected by the effective rate of comprehensive efficacy[OR=1.23,CI(1.16,1.32),P<0.00001],whole blood viscosity[MD=-0.76,95%CI(-1.32,-0.20),P=0.008],plasma viscosity[MD=-0.37,95%CI(-0.47,-0.27),P<0.00001],erythrocyte aggregation index[MD=-0.96,95%CI(-1.09,-0.84),P<0.00001],erythrocyte volume[MD=-0.09,95%CI(-0.11,-0.07),P<0.00001],fibrinogen[MD=-0.62,95%CI(-0.90,-0.33),P<0.00001].Conclusion:The results of Meta-analysis show that Fufang Xueshuantong combined with Fufang anisodine injection in the treatment of retinal vein obstruction may improve the hemorheology,and it could enhance clinical efficiency.However,the original literature is of low quality and the pooled results have some limitations.So the above conclusions need to be verified by more high-quality studies.
作者
吴美初
邢尧
丁珊
张富文
WU Mei-chu;XING Yao;DING Shan;ZHANG Fu-wen(Eye Shool of Chengdu University of Traditional Chinese Medicine,Chengdu 611137,Sichuan;Key Laboratory of Sichuan Province Ophthalmopathy Prevention&Cure and Visual Function Protection with TCM,Chengdu 611137,Sichuan)
出处
《中药与临床》
2024年第2期61-66,共6页
Pharmacy and Clinics of Chinese Materia Medica
基金
四川省中医药管理局“科学技术研究专项课题”(项目编号:2022CP3581)。
